Pipeline | S/N | Product number | Product introduction |
---|---|---|---|
Kidney Diseases |
1 | JYB1931 | With the advantages of clear mechanism and high specificity, it has entered the clinical stage |
Oncology | 2 | JYB1907 | Targeting multiple solid tumors, with significant in vivo efficacy and low toxicity, has entered the clinical stage |
3 | JMB2003 | Dual antibody products simultaneously target tumors and tumor microenvironment, with overlapping anti-tumor effects and significant preclinical effects | |
Respiratory Diseases | 4 | JYB1904 | The half-life is significantly extended compared to similar products, making it convenient to apply and meeting the needs of treatment compliance |
5 | JMB2004 | Affinity and positive animal efficacy results fill the clinical treatment gap |